Avinger to Announce Third Quarter 2024 Results on November 7, 2024
Rhea-AI Summary
Avinger (NASDAQ:AVGR), a commercial-stage medical device company specializing in intravascular image-guided catheter-based systems, has scheduled its third quarter 2024 financial results announcement for November 7, 2024, after market close. The company will host a conference call at 1:30pm PT/4:30pm ET. Investors can join via telephone at +1-973-528-0011 using passcode 442577 or through a live webcast available on the company's investor relations webpage. A replay will be available on Avinger's website after the call.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, AVGR gained 1.23%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
REDWOOD CITY, CA / ACCESSWIRE / October 29, 2024 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced that it will release its financial results for the third quarter 2024 after the close of trading on Thursday, November 7, 2024. The Company will host a conference call beginning at 1:30pm PT/4:30pm ET.
To join the call by telephone, please dial +1- 973-528-0011 and use passcode 442577. A live webcast of the conference call will be available online from the investor relations page of the Company's corporate website at www.avinger.com.
A replay of the webcast will be made available on Avinger's website, www.avinger.com, shortly after completion of the call.
About Avinger, Inc.
Avinger is a commercial-stage medical device company that designs and develops the first image-guided, catheter-based system for the diagnosis and treatment of patients with vascular disease in the peripheral and coronary arteries. Avinger is dedicated to radically changing the way vascular disease is treated through its Lumivascular platform, which currently consists of the Lightbox series of imaging consoles, the Ocelot and Tigereye® family of chronic total occlusion (CTO) catheters, and the Pantheris® family of atherectomy devices for the treatment of peripheral artery disease (PAD), estimated to affect more than 200 million people worldwide. Avinger is developing its first product application for the treatment of coronary artery disease (CAD), an image-guided system for CTO-crossing in the coronary arteries, which provides the opportunity to redefine a large and underserved market. Avinger is based in Redwood City, California. For more information, please visit www.avinger.com.
Follow Avinger on X and Facebook.
Investor Contact:
Matt Kreps
Darrow Associates Investor Relations
(214) 597-8200
mkreps@darrowir.com
SOURCE: Avinger, Inc.
View the original press release on accesswire.com
FAQ
When will Avinger (AVGR) release Q3 2024 earnings?
What time is Avinger's (AVGR) Q3 2024 earnings call?
How can I access Avinger's (AVGR) Q3 2024 earnings call?
